JP2024516619A5 - - Google Patents

Info

Publication number
JP2024516619A5
JP2024516619A5 JP2023565163A JP2023565163A JP2024516619A5 JP 2024516619 A5 JP2024516619 A5 JP 2024516619A5 JP 2023565163 A JP2023565163 A JP 2023565163A JP 2023565163 A JP2023565163 A JP 2023565163A JP 2024516619 A5 JP2024516619 A5 JP 2024516619A5
Authority
JP
Japan
Prior art keywords
cells
antibody
composition
optionally
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516619A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025651 external-priority patent/WO2022226130A1/en
Publication of JP2024516619A publication Critical patent/JP2024516619A/ja
Publication of JP2024516619A5 publication Critical patent/JP2024516619A5/ja
Pending legal-status Critical Current

Links

JP2023565163A 2021-04-21 2022-04-20 治療方法及びナチュラルキラー細胞組成物の投与方法 Pending JP2024516619A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177956P 2021-04-21 2021-04-21
US63/177,956 2021-04-21
PCT/US2022/025651 WO2022226130A1 (en) 2021-04-21 2022-04-20 Methods of treatment and dosing of natural killer cell compositions

Publications (2)

Publication Number Publication Date
JP2024516619A JP2024516619A (ja) 2024-04-16
JP2024516619A5 true JP2024516619A5 (enExample) 2025-09-04

Family

ID=81648459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565163A Pending JP2024516619A (ja) 2021-04-21 2022-04-20 治療方法及びナチュラルキラー細胞組成物の投与方法

Country Status (8)

Country Link
US (1) US20240197783A1 (enExample)
EP (1) EP4326288A1 (enExample)
JP (1) JP2024516619A (enExample)
KR (1) KR20240111702A (enExample)
CN (1) CN117915927A (enExample)
AU (1) AU2022262606A1 (enExample)
CA (1) CA3216410A1 (enExample)
WO (1) WO2022226130A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187181B (zh) * 2023-11-08 2024-03-19 普华赛尔生物医疗科技有限公司 包被组合物的方法及其应用
WO2025245399A1 (en) * 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells
CN119193483A (zh) * 2024-11-26 2024-12-27 北京国卫生物科技有限公司 一种体外高效扩增nk细胞的培养方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6168991B1 (en) 1999-06-25 2001-01-02 Lucent Technologies Inc. DRAM capacitor including Cu plug and Ta barrier and method of forming
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
JP7086928B2 (ja) * 2016-07-25 2022-06-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法
AU2019271146A1 (en) * 2018-05-14 2020-12-10 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses
KR20210077725A (ko) * 2018-10-17 2021-06-25 얀센 바이오테크 인코포레이티드 항-cd38 항체의 피하 투여를 제공하는 방법
EP3884041A2 (en) * 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
AU2020292965A1 (en) 2019-06-10 2022-01-27 Adc Therapeutics Sa Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent

Similar Documents

Publication Publication Date Title
Liu et al. NK cell-based cancer immunotherapy: from basic biology to clinical development
Hadiloo et al. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
Lamb et al. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
US20250034223A1 (en) Compositions and methods for expanding ex vivo natural killer cells and therapeutic uses thereof
Sutlu et al. Natural killer cell‐based immunotherapy in cancer: current insights and future prospects
Song et al. IL‐12/IL‐18‐preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation
CN113383071A (zh) 用于t细胞工程化的组合物和方法
JP2024516619A5 (enExample)
Torelli et al. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission
Baiocchi et al. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder
Servais et al. Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
US20210008110A1 (en) Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
Burns et al. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
WO2005009466A1 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
Maeda Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide
Gassner et al. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
F Krakow et al. Do we need full donor chimerism? How alloreactive cell therapies without substantial engraftment might treat hematologic cancers
Caruso et al. NK cells as adoptive cellular therapy for hematological malignancies: advantages and hurdles
Daudt et al. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines
Wendelboe et al. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?
US20230113157A1 (en) Compositions and methods for t cell engineering
Janakiram et al. Novel cell and immune engagers in optimizing tumor-specific immunity post-autologous transplantation in multiple myeloma
KR102032384B1 (ko) 제대혈 단핵세포에서의 자연살해세포의 제조 방법
Gillgrass et al. Recent Advances in the Use of NK Cells Against Cancer
Parisi et al. The More